Targeting the NMDA receptor-nitric oxide-cyclic GMP pathway to develop non-dopaminergic antipsychotic medications for schizophrenia
Schizophrenia is a devastating disorder that occurs in about 1% of the population worldwide. For over 30 years, it has been considered to be the result of dysfunctional brain dopaminergic pathways. However, dopaminergic antipsychotic drugs have proven effective for only some of the symptoms found in...
Na minha lista:
Principais autores: | Soares, Bruno Lobão, Oliveira, João Paulo Maia de, Machado-de-Sousa, João Paulo, Baker, Glen B., Dursun, Serdar, Hallak, Jaime E. C. |
---|---|
Formato: | article |
Idioma: | eng |
Publicado em: |
Associação Brasileira de Psiquiatria
|
Assuntos: | |
Endereço do item: | https://repositorio.ufrn.br/jspui/handle/123456789/25437 http://dx.doi.org/10.1590/S1516-44462011000300003 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Registros relacionados
-
Sodium nitroprusside, a nitric oxide donor for novel treatment of schizophrenia, may also modulate dopaminergic systems
por: Soares, Bruno Lobão, et al.
Publicado em: (2018) -
Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
por: Araújo, Aurigena Antunes de, et al.
Publicado em: (2018) -
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia
por: Araújo, Aurigena Antunes de, et al.
Publicado em: (2018) -
Thought disorder measured as random speech structure classifies negative symptoms and schizophrenia diagnosis 6 months in advance
por: Mota, Natália B., et al.
Publicado em: (2017) -
Factors associated with expression of extrapyramidal symptoms in users of atypical antipsychotics
por: Araújo, Aurigena Antunes de, et al.
Publicado em: (2018)